Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Launched by JONSSON COMPREHENSIVE CANCER CENTER · Aug 5, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new imaging tracer called 68Ga-FAPi-46 to see how it spreads and collects in the body, especially in cancer and normal tissues. This tracer is used with a special type of scan called a PET/CT, which combines two imaging methods to create detailed pictures of the inside of the body. The PET part shows where the tracer goes, highlighting cancer areas, while the CT part shows the exact shape and location of organs and tissues. By studying how this tracer behaves, doctors hope to improve cancer detection and better understand different types of solid tumors and blood cancers.
People who might join this study are adults (18 years or older) who have or are suspected to have certain cancers, such as breast, lung, prostate, bladder, brain, or many others listed in the trial. Participants need to be able to stay still during the scan, which takes about an hour, and must not be pregnant or nursing. If you join, you will receive the tracer through a small injection and then have a PET/CT scan to track where the tracer goes in your body. This is a phase 1 trial, meaning it’s an early study mainly focused on safety and understanding how the tracer acts in the body.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients with the following suspected or diagnosed cancer types:
- • Adrenal cancer
- • Anal cancer
- • Bladder cancer
- • Brain cancer
- • Breast cancer
- • Cancer of unknown primary (CUP)
- • Cervical cancer
- • Cholangiocarcinoma
- • Colorectal cancer
- • Esophageal cancer
- • Gastric cancer
- • Head and neck cancer
- • Hematologic cancer
- • Hepatocellular carcinoma
- • Lung cancer
- • Medullary thyroid cancer
- • Neuroendocrine neoplasias
- • Ovarian cancer
- • Pancreatic cancer
- • Penile cancer
- • Peritoneal cancer
- • Pleural cancer
- • Prostate cancer
- • Sarcoma
- • Salivary gland cancer
- • Solitary fibrous tumor
- • Skin cancer
- • Testicular cancer
- • Thymus cancer
- • Thyroid cancer
- • Urothelial cancer
- • Uterus cancer
- • Vaginal cancer
- • Patients are ≥ 18 years old at the time of the radiotracer administration
- • Patient can provide written informed consent
- • Patient is able to remain still for duration of imaging procedure (up to one hour)
- Exclusion Criteria:
- • Patient is pregnant or nursing
- • Patient has underlying disease which, based on the judgment of the investigator, might interfere with the collection of high-quality data
About Jonsson Comprehensive Cancer Center
The Jonsson Comprehensive Cancer Center (JCCC) is a leading research and treatment institution dedicated to advancing cancer prevention, diagnosis, and treatment through innovative clinical trials and cutting-edge research. Affiliated with the University of California, Los Angeles (UCLA), the JCCC integrates a multidisciplinary approach, bringing together experts in oncology, genetics, and public health to foster collaboration and translate scientific discoveries into effective therapies. With a commitment to improving patient outcomes and quality of life, the JCCC conducts a wide range of clinical trials aimed at addressing various cancer types, ensuring that patients have access to the most advanced therapeutic options available.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Jeremie Calais
Principal Investigator
UCLA / Jonsson Comprehensive Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported